Suman Malempati

Summary

Affiliation: Oregon Health and Science University
Country: USA

Publications

  1. doi request reprint Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies
    Suman Malempati
    Department of Pediatrics, Oregon Health and Science University, Portland, Oregon 97239 3098, USA
    Pediatr Blood Cancer 59:5-10. 2012
  2. ncbi request reprint Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group
    Suman Malempati
    Department of Pediatrics, Oregon Health and Science University, Portland, OR 97239 3098, USA
    J Clin Oncol 25:1505-11. 2007
  3. ncbi request reprint Outcome after relapse among children with standard-risk acute lymphoblastic leukemia: Children's Oncology Group study CCG-1952
    Suman Malempati
    Department of Pediatrics, Oregon Health and Science University, 3181 SW Sam Jackson Park Rd, CDRC P, Portland, OR 97239 3098, USA
    J Clin Oncol 25:5800-7. 2007
  4. pmc Rhabdomyosarcoma in infants younger than 1 year: a report from the Children's Oncology Group
    Suman Malempati
    Department of Pediatrics, Oregon Health and Science University, Portland, OR 97239 3098, USA
    Cancer 117:3493-501. 2011
  5. pmc Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group
    Suman Malempati
    Department of Pediatrics, Oregon Health and Science University, 3181 SW Sam Jackson Park Rd, CDRC P, Portland, OR 97239 3098, USA
    J Clin Oncol 30:256-62. 2012
  6. doi request reprint Emergency department presentation of childhood cancer
    Kellie J Nazemi
    Division of Pediatric Hematology Oncology, Department of Pediatrics, Oregon Health and Science University, CDRC P, Portland, OR, USA
    Emerg Med Clin North Am 27:477-95. 2009
  7. doi request reprint Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma
    Jinu Abraham
    Greehey Children s Cancer Research Institute, University of Texas Health Science Center, San Antonio, Texas, USA
    Mol Cancer Ther 10:697-707. 2011
  8. pmc Overcoming autopsy barriers in pediatric cancer research
    Jennifer L Alabran
    Pediatric Cancer Biology Program, Papé Family Pediatric Research Institute, Oregon Health and Science University, Portland, OR 97239 3098, USA
    Pediatr Blood Cancer 60:204-9. 2013
  9. doi request reprint Prevalence of transient hyperglycemia during induction chemotherapy for pediatric acute lymphoblastic leukemia
    Stefanie R Lowas
    Division of Pediatric Hematology Oncology, Doernbecher Children s Hospital, Oregon Health and Science University, Portland, Oregon, USA
    Pediatr Blood Cancer 52:814-8. 2009

Collaborators

Detail Information

Publications9

  1. doi request reprint Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies
    Suman Malempati
    Department of Pediatrics, Oregon Health and Science University, Portland, Oregon 97239 3098, USA
    Pediatr Blood Cancer 59:5-10. 2012
    ..This review describes the IRSG and COG experience with RMS, presents the current risk stratification definitions, and provides rationale for the current generation of COG RMS studies...
  2. ncbi request reprint Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group
    Suman Malempati
    Department of Pediatrics, Oregon Health and Science University, Portland, OR 97239 3098, USA
    J Clin Oncol 25:1505-11. 2007
    ..The purpose of this study was to determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLTs), and pharmacokinetic properties of pemetrexed in children...
  3. ncbi request reprint Outcome after relapse among children with standard-risk acute lymphoblastic leukemia: Children's Oncology Group study CCG-1952
    Suman Malempati
    Department of Pediatrics, Oregon Health and Science University, 3181 SW Sam Jackson Park Rd, CDRC P, Portland, OR 97239 3098, USA
    J Clin Oncol 25:5800-7. 2007
    ..However, prognosis after relapse continues to be poor. We examined postrelapse outcomes of children initially treated on the Children's Cancer Group CCG-1952 study...
  4. pmc Rhabdomyosarcoma in infants younger than 1 year: a report from the Children's Oncology Group
    Suman Malempati
    Department of Pediatrics, Oregon Health and Science University, Portland, OR 97239 3098, USA
    Cancer 117:3493-501. 2011
    ..Rhabdomyosarcoma (RMS), the most common soft-tissue sarcoma in children, occurs less commonly in infants. Historically, poorer outcomes have been reported for infants diagnosed with RMS than for older children...
  5. pmc Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group
    Suman Malempati
    Department of Pediatrics, Oregon Health and Science University, 3181 SW Sam Jackson Park Rd, CDRC P, Portland, OR 97239 3098, USA
    J Clin Oncol 30:256-62. 2012
    ..This study was designed to assess the toxicities, pharmacokinetics, and pharmacodynamics of cixutumumab in children to determine a recommended phase II dose and to assess antitumor activity in Ewing sarcoma (ES)...
  6. doi request reprint Emergency department presentation of childhood cancer
    Kellie J Nazemi
    Division of Pediatric Hematology Oncology, Department of Pediatrics, Oregon Health and Science University, CDRC P, Portland, OR, USA
    Emerg Med Clin North Am 27:477-95. 2009
    ..This article reviews the most common presentations of childhood cancer and the appropriate initial management in the Emergency Department...
  7. doi request reprint Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma
    Jinu Abraham
    Greehey Children s Cancer Research Institute, University of Texas Health Science Center, San Antonio, Texas, USA
    Mol Cancer Ther 10:697-707. 2011
    ..These results point to the potential therapeutic importance of simultaneous targeting of Igf1r and Her2 to abrogate resistance...
  8. pmc Overcoming autopsy barriers in pediatric cancer research
    Jennifer L Alabran
    Pediatric Cancer Biology Program, Papé Family Pediatric Research Institute, Oregon Health and Science University, Portland, OR 97239 3098, USA
    Pediatr Blood Cancer 60:204-9. 2013
    ..The purpose of this study was to identify barriers to autopsies and develop guidelines for requesting autopsies for research purposes...
  9. doi request reprint Prevalence of transient hyperglycemia during induction chemotherapy for pediatric acute lymphoblastic leukemia
    Stefanie R Lowas
    Division of Pediatric Hematology Oncology, Doernbecher Children s Hospital, Oregon Health and Science University, Portland, Oregon, USA
    Pediatr Blood Cancer 52:814-8. 2009
    ..This study examined the prevalence of TH in a cohort of pediatric ALL patients and the impact on TH of type of steroid or asparaginase used and of risk factors such as age, gender, and overweight...